Categories
Videos

The Pfizer documents – Dr. John Campbell

“This is quite alarming…”


Public Health and Medical Professionals for Transparency, Pfizer / FDA FOI https://phmpt.org

Adverse event reports
01 December 2020 through 28 February 2021

Cumulatively, through 28 February 2021, a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 events. Most cases (34,762) were received from United States (13,739), United Kingdom (13,404) Italy (2,578), Germany (1,913), France (1,506), Portugal (866) and Spain (756) the remaining 7,324 were distributed among 56 other countries. Fatal, 1,223 Since Dec. 11, 2020, the Pfizer-BioNTech COVID-19 Vaccine has been available under EUA https://www.fda.gov/news-events/press… (Approval, 21st August 2021) Acting FDA Commissioner Janet Woodcock, M.D. While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated. Today’s milestone puts us one step closer to altering the course of this pandemic in the U.S. System Organ Classes (SOCs) that contained the greatest number (≥2%) of events, in the overall dataset, were General disorders and administration site conditions (51,335 AEs), Nervous system disorders (25,957), Musculoskeletal and connective tissue disorders (17,283), Gastrointestinal disorders (14,096), Skin and subcutaneous tissue disorders (8,476), Respiratory, thoracic and mediastinal disorders (8,848), Infections and infestations (4,610), Injury, poisoning and procedural complications (5,590), and Investigations (3,693). Cardiovascular AESIs Number of cases: 1403 (3.3% of the total PM dataset), of which 241 are medically confirmed and 1162 are non-medically confirmed; 5. SUMMARY AND CONCLUSION Review of the available data for this cumulative PM experience, confirms a favorable benefit: risk balance for BNT162b2. Peter Marks, M.D., Ph.D., director of FDA’s Center for Biologics Evaluation and Research “Our scientific and medical experts conducted an incredibly thorough and thoughtful evaluation of this vaccine. We evaluated scientific data and information included in hundreds of thousands of pages, conducted our own analyses of Comirnaty’s safety and effectiveness, and performed a detailed assessment of the manufacturing processes, including inspections of the manufacturing facilities,” “….. the public is counting on safe and effective vaccines. The public and medical community can be confident that although we approved this vaccine expeditiously, it was fully in keeping with our existing high standards for vaccines in the U.S.” https://childrenshealthdefense.org/de… Austria https://www.nytimes.com/live/2022/03/… Karoline Edtstadler the law, passed in January, in force since early February, not proportionate, relatively mild symptoms experienced by most people who contract Omicron

Categories
Publications

5.3.6 Cumulative Analysis of Post-Authorization Adverse Event Reports of PF-07302048 (BNT162B2) Received Through 28-FEB-2021 – Pfizer

Reference is made to the Request for Comments and Advice submitted 04 February 2021 regarding Pfizer/BioNTech’s proposal for the clinical and post-authorization safety data package for the Biologics License Application (BLA) for our investigational COVID-19 Vaccine (BNT162b2). Further reference is made to the Agency’s 09 March 2021 response to this request, and specifically, the following request from the Agency.

The download link is available from Public Health and Medical Professionals for Transparency.

Important points from this report include:

  • A seven-year-old experienced a stroke.
  • One child and one infant suffered facial paralysis.
  • One infant had a kidney adverse event, either kidney injury or failure.
  • Of the 34 cases, 24 (71%) were classified as serious.
  • Predominantly female patients were affected — at least 25 of 34 (73.5%) patients.
  • Table 6 reports 34 cases of use in pediatric individuals. However, 28 additional cases were excluded because details such as height and weight were “not consistent with pediatric subjects.”
  • Ages ranged from two months to nine years, with median 4.0 years, which means half the children were under four years of age.
  • 132 adverse events were reported in the 34 children – i.e., an average of 3.88 AEs per child.

Summary from Daily Clout journalists:

https://archive.today/2022.12.29-231302/https://www.phmpt.org/wp-content/uploads/2022/04/reissue_5.3.6-postmarketing-experience.pdf